Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PRLD with free AI briefings, catalyst countdowns, and dilution alerts.

PRLD · Prelude Therapeutics Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$151.8M Cash on Hand
24.4mo Cash Runway
Follow PRLD by email Get an email when PRLD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PRLD, unsubscribe in one click. Privacy

📣 What PRLD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
SMARCA2 Degrader PRT3789 Advanced Solid Tumor Phase 2 · NCT06682806 Terminated
Myeloid Cell Leukemia 1 Inhibitor PRT1419 Acute Myeloid Leukemia Phase 1 · NCT05107856 Terminated
Zanubrutinib Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1 · NCT05665530 Completed
PRMT5 Inhibitor PRT811 Advanced Solid Tumor Phase 1 · NCT04089449 Completed
SMARCA2 Degrader PRT7732 Advanced Solid Tumor Phase 1 · NCT06560645 Terminated
Protein Arginine Methyltransferase 5 Inhibitor… Relapsed/Refractory Advanced Solid Tumors Phase 1 · NCT03886831 Completed
CDK4/6 Inhibitor PRT3645 Breast Cancer Phase 1 · NCT05538572 Completed
CDK9 Inhibitor PRT2527 Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1 · NCT05665530 Completed
PRT13722 Breast Cancer Phase 1 · NCT07905001 Recruiting
JAK2V617F Inhibitor PRT12396 Polycythemia Vera (PV) Phase 1 · NCT07469891 Recruiting
Imlunestrant Breast Cancer Phase 1 · NCT07905001 Recruiting

Also used in these trials (approved or third-party drugs, not PRLD's own candidates): Pembrolizumab, Venetoclax, Abemaciclib, Fulvestrant, Docetaxel Anhydrous, Azacitidine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PRLD holds $151.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $18.6M/quarter from operations, an estimated runway of 24.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRLD files for a raise →

👥 Who Owns PRLD

Insiders 18% Other 5%+ holders 4.2% Institutions (125 holders) 77.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Baker Bros. Advisors LP Institution (13G, 5%+) 10,295,301 12.86% 2026-04-20
Krishna Vaddi
CEO, Director · +837,000 options
Insider 6,745,647 8.42% 2025-12-31
RA CAPITAL MANAGEMENT, L.P.
10% owner · +1.41M options
Insider 6,475,882 8.09% 2026-04-27
Soleus Capital Management, L.P. 5%+ holder (13G) 3,378,378 4.22% 2026-04-21
David P Bonita
Director, 10% owner · +76,000 options
Insider 526,300 0.66% 2026-04-21
ORBIMED ADVISORS LLC
Director, 10% owner
Includes shares also reported by David P Bonita, counted once
Insider 526,300 0.66% 2026-04-21
Andrew Combs
Chief Chemistry Officer · +405,000 options
Insider 480,123 0.60% 2025-03-25
Sean P. Brusky
Chief Business Officer
Insider 100,000 0.12% 2026-03-05
Jane Huang
President, CMO · +218,750 options
Insider 86,917 0.11% 2025-10-04

Share count 80,070,666 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PRLD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRLD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.